MIV Therapeutics' stent-coating study indicates long-term biocompatibility

By Angela McDaniels

Seattle, Oct. 25 - MIV Therapeutics Inc. said interim results of a long-term animal study of its Hydroxyapatite (HAp) stent-coating technology indicate long-term biocompatibility.

An independent research organization presented the results at the 17th annual Transcatheter Cardiovascular Therapeutics 2005 conference in Washington, D.C.

Dr. Greg L. Kaluza, scientific director of the Center for Research in Cardiovascular Interventions of The Methodist Hospital Research Institute in Houston, Texas, was the lead investigator for the animal trial of the MIV technology and presented his team's findings at the conference.

The presentation included scientific data gathered three months after implanting stents coated with highly crystallinic calcium phosphate ceramic into the coronary arteries of Yucatan minipigs, MIV said.

"In the field of vascular stents and stent coatings, two pivotal, fundamental issues of concern are biocompatibility and safety," Dr. Kaluza said. "The three-month data allowed us to conclude that the ultra-thin hydroxyapatite coating... showed promise of an excellent long-term biocompatibility and thus makes an attractive candidate for a next-generation stent coating."

MIV Therapeutics Inc. is based in Vancouver, B.C., and develops biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.